TY - JOUR T1 - Can Vaccine Prioritization Reduce Disparities in Covid-19 Burden for Historically Marginalized Populations? JF - medRxiv DO - 10.1101/2021.07.27.21261210 SP - 2021.07.27.21261210 AU - Erik Rosenstrom AU - Jessica Mele AU - Julie Ivy AU - Maria Mayorga AU - Mehul Patel AU - Kristen Hassmiller Lich AU - Karl Johnson AU - Paul Delamater AU - Pinar Keskinocak AU - Ross Boyce AU - Raymond Smith AU - Julie L. Swann Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/30/2021.07.27.21261210.abstract N2 - Importance Nationally stated goals for distributing SARS-CoV-2 vaccines included to reduce COVID-19 mortality, morbidity, and inequity using prioritization groups. However, the impact of these prioritization strategies is not well understood, particularly their effect on health inequity in COVID-19 burden for historically marginalized racial and ethnic populations.Objective To assess the impact of vaccination prioritization and operational strategies on disparities in COVID-19 burden among historically marginalized populations, and on mortality and morbidity by race and ethnicity.Design We use an agent-based simulation model of North Carolina to project SARS-CoV-2 infections and COVID-19-associated deaths (mortality), hospitalizations (morbidity), and cases over 18 months (7/1/2020-12/31/2021) with vaccine distribution beginning 12/13/2020 to frontline medical and people 75+, assuming initial uptake similar to influenza vaccine. We study two-stage subsequent prioritization including essential workers (“essential”), adults 65+ (“age”), adults with high-risk health conditions, HMPs, or people in low income tracts, with eligibility for the general population in the third stage. For age-essential and essential-age strategies, we also simulated maximal uptake (100% for HMP or 100% for everyone), and we allowed for distribution to susceptible-only people.Results Prioritizing Age then Essential had the largest impact on mortality (2.5% reduction from no prioritization); Essential then Age had the lowest morbidity and reduced infections (4.2% further than Age-Essential) without significantly impacting mortality. Under each prioritization scenario, the age-adjusted mortality burden for HMPs is higher (e.g., 33.3-34.1% higher for the Black population, 13.3%-17.0% for the Hispanic population) compared to the White population, and the gap grew under some prioritizations. In the Age-Essential strategy, the burden on HMPs decreases only when uptake is increased to 100% in HMPs. However, the Black population still had the highest mortality rate even with the Susceptible-Only distribution.Conclusions and Relevance Simulation results show that prioritization strategies have differential impact on mortality, morbidity, and disparities overall and by race and ethnicity. If prioritization schemes were not paired with increased uptake in HMPs, disparities did not improve and could worsen. Although equity was one of the tenets of vaccine distribution, the vaccination strategies publicly outlined are insufficient to remove and may exacerbate disparities between racial and ethnic groups, thus targeted strategies are needed for the future.Competing Interest StatementDr. Patel reported receiving grants from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and from the Council of State and Territorial Epidemiologists (CSTE) during the conduct of the study. Mr. Rosenstrom reported receiving support from the Centers for Disease Control and Prevention (CDC), the Council of State and Territorial Epidemiologists (CSTE), and NCATS/NIH during the conduct of the study. Ms. Mele reported receiving support from the CDC, CSTE, and NCATS/NIH during the conduct of the study. Dr. Ivy reported receiving grants from the CDC, CSTE, NCATS, and NC State University during the conduct of the study. Dr. Mayorga reported receiving grants from the NCATS/NIH, CSTE, CDC, and NC State University during the conduct of the study. Dr. Keskinocak reported receiving grants from CDC, CSTE, and Georgia Institute of Technology during the conduct of the study. Dr. Swann reported receiving grants from NCATS/NIH, CDC, CSTE, and NC State University during the conduct of the study. No other disclosures were reported.Clinical TrialWe believe that this study does not meet the definition of a clinical trial.Funding StatementThis research was supported by grant UL1TR002489 from the NCATS/NIH; Cooperative Agreement NU38OT000297 from the CSTE and the CDC; and grant K01AI151197 from the National Institute of Allergy and Infectious Diseases/NIH (Dr Delamater). The research also received partial support from the Georgia Institute of Technology and NC State University.The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript uses publicly available data from the US Census, published estimates of disease parameters, and data obtained from SafeGraph on mobility across communities. The Institutional Review Board of NC State reviewed the project and determined that no IRB approval would be needed since identifiers are not included with the dataset and individuals cannot be directly or indirectly identified.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis manuscript uses publicly available data from the US Census, published estimates of disease parameters, data obtained from SafeGraph on mobility across communities, and estimates obtained from the Covid-19 Case Surveillance Restricted Access Detailed Data. ER -